Production (Stage)
Anavex Life Sciences Corp.
AVXL
$7.53
-$0.14-1.83%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.13% | 2.35% | -6.61% | -16.88% | -13.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.59% | 8.13% | -4.26% | -11.25% | -11.58% |
| Operating Income | -11.59% | -8.13% | 4.26% | 11.25% | 11.58% |
| Income Before Tax | -16.53% | -8.24% | 9.06% | 18.90% | 22.50% |
| Income Tax Expenses | -730.43% | -807.41% | -2,828.57% | -146.65% | -107.01% |
| Earnings from Continuing Operations | -16.13% | -7.73% | 9.48% | 19.60% | 23.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.13% | -7.73% | 9.48% | 19.60% | 23.03% |
| EBIT | -11.59% | -8.13% | 4.26% | 11.25% | 11.58% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -12.03% | -3.08% | 13.85% | 23.81% | 26.81% |
| Normalized Basic EPS | -12.44% | -5.83% | 11.73% | 21.66% | 25.01% |
| EPS Diluted | -12.03% | -3.08% | 13.85% | 23.81% | 26.81% |
| Normalized Diluted EPS | -12.44% | -5.83% | 11.73% | 21.66% | 25.01% |
| Average Basic Shares Outstanding | 3.61% | 4.14% | 4.62% | 5.23% | 5.21% |
| Average Diluted Shares Outstanding | 3.61% | 4.14% | 4.62% | 5.23% | 5.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |